Pulmatrix, Inc. a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology, has been granted two patents from the U.S. Patent and Trademark Office, covering the composition of matter for iSPERSE™ as well as methods for treating patients using respirable dry powders.
iSPERSE (inhaled small particles easily respirable and emitted) is a new platform for inhaled drug delivery based on unique properties: high drug load, dense, engineered particles that enable an efficient dispersibility and delivery to the lung airways. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis.
Dry powder technologies have many commercial advantages over nebulized liquid preparations, such as improved portability, speed of dosing, ease of use, and enhanced intellectual property protection.
The technologies have the potential to improve or enable new treatment approaches for patients with lung disease or to improve the efficiency in the delivery of medication to the lungs. Pulmatrix has now 36 issued patents globally covering the iSPERSE™ technology through at least 2030.
“These issuances build upon previously issued international patents and reflect our aggressive strategy to broadly protect the global IP position of our core iSPERSE™ technology,” said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. “Our issued and pending patents are the result of the research and development conducted in our labs and which formed the basis for our most advanced clinical-stage candidate, a branded generic bronchodilator for COPD, and our proprietary development candidate, an anti-fungal for cystic fibrosis. We look forward to the receipt of additional patents covering distinct as well as overlapping components and combinations of our iSPERSE™ technology and drug development candidates.”
iSPERSE allows the efficient airway delivery of higher drug loads in smaller masses of inhaled powder. In contrast to standard DP technologies, these powders are small but highly dispersible and relatively flow rate independent with high emitted doses achieved even at low flow rates.
This targeted airway delivery of drugs also allows for a reduction in systemic exposure and potential adverse events. In contrast with other standard inhalation technologies, iSPERSE™ is also flow rate independent, providing reliable dose delivery across patient populations irrespective of their lung function status.
“These patent grants further validate the novelty and relevance of the iSPERSE™ technology,” said in the news release David Hava, Ph.D., chief scientific officer for Pulmatrix. “Specifically, they recognize the uniqueness of our ability to produce aerodynamically small, dense powders that maintain remarkable dispersibility profiles across a range of drug classes and underscore the differentiation of our technology from conventional and earlier particle engineering approaches.”